Anju George
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Anju George has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Dharshini Sathishkumar
Christian Medical College 30 Department of Dermatology Vellore
4 shared publications Meera Thomas
Department of Pathology, Christian Medical College and Hospital, Vellore, Tamil Nadu, India
3 shared publicationsRenu George
Retired Professor, Department of Dermatology, Venereology and Leprosy, Christian Medical College, Vellore, Tamil Nadu, 632004, India
3 shared publications- Renu George
Department of Dermatology, Christian Medical College and Hospital, Vellore, Tamil Nadu, India
3 shared publications - Alejandro Molina-Leyva
Dermatology Department Hospital Universitario Virgen de las Nieves‐Ibs. Granada Granada Spain
2 shared publications - Ankan Gupta
Department of Dermatology, Christian Medical College and Hospital, Vellore, Tamil Nadu, India
2 shared publications
Latest Publications
- 13 September 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
Disease progression in hidradenitis suppurativa: A multidimensional framework
Hidradenitis suppurativa (HS) is increasingly recognized as a progressive inflammatory disease in which recurrent follicular inflammation, tunnel formation and systemic inflammation drive cumulative, largely irreversible tissue damage, quality‐of‐life impairment and cardiometabolic comorbidity. Despite this, no consensus definition of disease progression exists. This review synthesizes current evidence to propose a working, multidimensional framework for progression in HS and to map its determinants, detection tools and consequences. We frame progression along six complementary dimensions grouped in three blocks—objective severity (Hurley transition, International Hidradenitis Suppurativa Severity Score System [IHS4] category shift), anatomical extension (extra‐ and intraregional spread) and cumulative disease burden (secondary complications and patient‐reported impact)—aligned with current European guidelines for therapeutic escalation. Available longitudinal data show that incidence and speed of progression depend strongly on care setting and assessment method, with tertiary cohorts assessed clinically and by ultrasound reporting incidences of approximately 37% over ~2 years and self‐reported community cohorts substantially lower. Independent risk factors cluster into demographic‐familial, phenotypic‐anatomical, lifestyle‐metabolic, laboratory and comorbidity domains, with early‐onset disease, smoking, inflammatory bowel disease, Down syndrome and pilonidal sinus as the most consistent signals. Phenotype frameworks converge on a higher‐risk profile of male, smoker patients with severe acne and lower‐body involvement. Genotype shapes phenotype, with γ‐secretase/Notch variants driving an occlusion‐dominant course and inflammasome variants (PASH, PAPASH, PAPA, SAPHO) a more systemic one; heritability approaches 77%. Ultrasound refines staging, detects subclinical microtunnels and identifies the inflamed non‐draining tunnel that defines a within‐lesion window of opportunity. Progression has tangible cutaneous, psychosocial, systemic, metabolic and cardiovascular consequences, making early recognition a clinical imperative; disease modification within a limited therapeutic window remains a plausible and testable paradigm rather than a demonstrated fact.
- 13 September 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
Disease progression in hidradenitis suppurativa: A multidimensional framework
Hidradenitis suppurativa (HS) is increasingly recognized as a progressive inflammatory disease in which recurrent follicular inflammation, tunnel formation and systemic inflammation drive cumulative, largely irreversible tissue damage, quality‐of‐life impairment and cardiometabolic comorbidity. Despite this, no consensus definition of disease progression exists. This review synthesizes current evidence to propose a working, multidimensional framework for progression in HS and to map its determinants, detection tools and consequences. We frame progression along six complementary dimensions grouped in three blocks—objective severity (Hurley transition, International Hidradenitis Suppurativa Severity Score System [IHS4] category shift), anatomical extension (extra‐ and intraregional spread) and cumulative disease burden (secondary complications and patient‐reported impact)—aligned with current European guidelines for therapeutic escalation. Available longitudinal data show that incidence and speed of progression depend strongly on care setting and assessment method, with tertiary cohorts assessed clinically and by ultrasound reporting incidences of approximately 37% over ~2 years and self‐reported community cohorts substantially lower. Independent risk factors cluster into demographic‐familial, phenotypic‐anatomical, lifestyle‐metabolic, laboratory and comorbidity domains, with early‐onset disease, smoking, inflammatory bowel disease, Down syndrome and pilonidal sinus as the most consistent signals. Phenotype frameworks converge on a higher‐risk profile of male, smoker patients with severe acne and lower‐body involvement. Genotype shapes phenotype, with γ‐secretase/Notch variants driving an occlusion‐dominant course and inflammasome variants (PASH, PAPASH, PAPA, SAPHO) a more systemic one; heritability approaches 77%. Ultrasound refines staging, detects subclinical microtunnels and identifies the inflamed non‐draining tunnel that defines a within‐lesion window of opportunity. Progression has tangible cutaneous, psychosocial, systemic, metabolic and cardiovascular consequences, making early recognition a clinical imperative; disease modification within a limited therapeutic window remains a plausible and testable paradigm rather than a demonstrated fact.
- Open Access
- 25 August 2026
- Published by Wiley in JEADV Clinical Practice
Therapeutic Inertia in Hidradenitis Suppurativa: Could Defensive Medicine Play a Role?
- 25 August 2026
- Published by Wiley in JEADV Clinical Practice
Open AccessTherapeutic Inertia in Hidradenitis Suppurativa: Could Defensive Medicine Play a Role?
- Open Access
- 1 May 2026
- Published by AME Publishing Company in AME Case Reports
- Vol. 10, 81
Eruptive zoophilic dermatophytosis and the expanding role of molecular diagnostics
Eruptive zoophilic dermatophytosis and the expanding role of molecular diagnostics
- 1 May 2026
- Published by AME Publishing Company in AME Case Reports
- Vol. 10, 81
Open AccessEruptive zoophilic dermatophytosis and the expanding role of molecular diagnostics
Eruptive zoophilic dermatophytosis and the expanding role of molecular diagnostics
- 19 February 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (9) , 1944-1946
Coexisting Papulonecrotic Tuberculid and Erythema Induratum in Polyresistant Tuberculous Lymphadenitis
- 19 February 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (9) , 1944-1946
Coexisting Papulonecrotic Tuberculid and Erythema Induratum in Polyresistant Tuberculous Lymphadenitis
- 27 January 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (2) , 138-140
Experiences and feedback from the JEADV Junior Editor Programme
- 27 January 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (2) , 138-140
Experiences and feedback from the JEADV Junior Editor Programme
- Open Access
- 10 August 2025
- Published by Wiley in JEADV Clinical Practice
- Vol. 4 (5) , 1239-1243
Expanding the Interface: Overlooked Dermatologic Disorders With Ocular Involvement
- 10 August 2025
- Published by Wiley in JEADV Clinical Practice
- Vol. 4 (5) , 1239-1243
Open AccessExpanding the Interface: Overlooked Dermatologic Disorders With Ocular Involvement
- 27 May 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (2)
Re‐exploring management of hidradenitis suppurativa: A call for imaging and procedural inclusion
- 27 May 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 40 (2)
Re‐exploring management of hidradenitis suppurativa: A call for imaging and procedural inclusion
- Open Access
- 19 May 2025
- Published by Wiley in JEADV Clinical Practice
- Vol. 4 (4) , 902-904
The Understudied Landscape of Hidradenitis Suppurativa in Asian Skin of Colour Populations
- 19 May 2025
- Published by Wiley in JEADV Clinical Practice
- Vol. 4 (4) , 902-904
Open AccessThe Understudied Landscape of Hidradenitis Suppurativa in Asian Skin of Colour Populations
- 23 December 2024
- Published by Wiley in Pediatric Dermatology
- Vol. 42 (3) , 615-619
Vitamin D Dependent Rickets 2A With Alopecia: Three Cases With Novel Genetic Variants
Vitamin D‐dependent rickets type 2A (VDDR2A) is a rare cause of infantile‐onset alopecia, characterized by severe hypotrichosis, small cutaneous cysts, early‐onset treatment‐resistant rickets, and hypocalcemia. Alopecia, often starting a few weeks to months after birth, may be the presenting feature. We present three cases of VDDR2A with genetic variants in the vitamin D receptor (VDR) gene, their clinical features and biochemical parameters. This case series emphasizes that early identification of this rare cause of alopecia and treating the metabolic abnormalities can improve bone health.
- 23 December 2024
- Published by Wiley in Pediatric Dermatology
- Vol. 42 (3) , 615-619
Vitamin D Dependent Rickets 2A With Alopecia: Three Cases With Novel Genetic Variants
Vitamin D‐dependent rickets type 2A (VDDR2A) is a rare cause of infantile‐onset alopecia, characterized by severe hypotrichosis, small cutaneous cysts, early‐onset treatment‐resistant rickets, and hypocalcemia. Alopecia, often starting a few weeks to months after birth, may be the presenting feature. We present three cases of VDDR2A with genetic variants in the vitamin D receptor (VDR) gene, their clinical features and biochemical parameters. This case series emphasizes that early identification of this rare cause of alopecia and treating the metabolic abnormalities can improve bone health.